Cargando…
TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA
BACKGROUND: DNA methylation is an essential component for integrative diagnosis of gliomas. Methylation subtype prediction of gliomas is currently done via sample extraction of high-quality DNA (~1ug), methylome profiling, followed by probe identification, curation and subsequent analysis via differ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992223/ http://dx.doi.org/10.1093/noajnl/vdab024.084 |
_version_ | 1783669329044176896 |
---|---|
author | Lita, Adrian Sjöberg, Joel Filipescu, Stefan Celiku, Orieta Petre, Luigia Gilbert, Mark Noushmehr, Houtan Petre, Ion Larion, Mioara |
author_facet | Lita, Adrian Sjöberg, Joel Filipescu, Stefan Celiku, Orieta Petre, Luigia Gilbert, Mark Noushmehr, Houtan Petre, Ion Larion, Mioara |
author_sort | Lita, Adrian |
collection | PubMed |
description | BACKGROUND: DNA methylation is an essential component for integrative diagnosis of gliomas. Methylation subtype prediction of gliomas is currently done via sample extraction of high-quality DNA (~1ug), methylome profiling, followed by probe identification, curation and subsequent analysis via different random forest classifiers. However, the DNA methylation classification is not always available for all the samples. Examples include when the existing material is not suitable for methylation profiling or the sample is very limiting. Therefore, we hypothesized that Raman spectroscopy might be suitable to predict the glioma methylome, based upon its ability to create a molecular fingerprint of the tumor and would provide biological insights unknown before. METHODS: Coherent Raman Spectroscopy was used for molecular fingerprinting of the regions of interest using 1mm(2) FFPE tissue spots from 39 patient samples with LGm1 to LGm6 methylation subtypes. Spectral information was then used to train a convolutional neural network (CNN) and develop a prediction algorithm, capable of detecting the glioma methylation subtypes. 70 % of the dataset was used for model training while the remaining 30% for validation. Oversampling was used to obtain a subtype-balanced data distribution. In addition, supervised wrapper methods and random forests were used to identify the top 50 most discriminatory Raman frequencies out of 1738. RESULTS: We demonstrate that Raman spectroscopy can accurately and rapidly classify gliomas according to their methylation subtype from achieved FFPE samples, which are routinely present in pathological laboratories as a complementary mean to obtain this important classification when other analyses are not available. The most discriminatory frequencies show differential spectral intensities depending upon the glioma subtypes across the larger areas of the tissue. CONCLUSIONS: The non-destructive nature of this method and the ability to be applied on FFPE samples directly, allows the histopathologist to reuse of the same slide for subsequent staining and downstream analyses. |
format | Online Article Text |
id | pubmed-7992223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79922232021-03-31 TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA Lita, Adrian Sjöberg, Joel Filipescu, Stefan Celiku, Orieta Petre, Luigia Gilbert, Mark Noushmehr, Houtan Petre, Ion Larion, Mioara Neurooncol Adv Supplement Abstracts BACKGROUND: DNA methylation is an essential component for integrative diagnosis of gliomas. Methylation subtype prediction of gliomas is currently done via sample extraction of high-quality DNA (~1ug), methylome profiling, followed by probe identification, curation and subsequent analysis via different random forest classifiers. However, the DNA methylation classification is not always available for all the samples. Examples include when the existing material is not suitable for methylation profiling or the sample is very limiting. Therefore, we hypothesized that Raman spectroscopy might be suitable to predict the glioma methylome, based upon its ability to create a molecular fingerprint of the tumor and would provide biological insights unknown before. METHODS: Coherent Raman Spectroscopy was used for molecular fingerprinting of the regions of interest using 1mm(2) FFPE tissue spots from 39 patient samples with LGm1 to LGm6 methylation subtypes. Spectral information was then used to train a convolutional neural network (CNN) and develop a prediction algorithm, capable of detecting the glioma methylation subtypes. 70 % of the dataset was used for model training while the remaining 30% for validation. Oversampling was used to obtain a subtype-balanced data distribution. In addition, supervised wrapper methods and random forests were used to identify the top 50 most discriminatory Raman frequencies out of 1738. RESULTS: We demonstrate that Raman spectroscopy can accurately and rapidly classify gliomas according to their methylation subtype from achieved FFPE samples, which are routinely present in pathological laboratories as a complementary mean to obtain this important classification when other analyses are not available. The most discriminatory frequencies show differential spectral intensities depending upon the glioma subtypes across the larger areas of the tissue. CONCLUSIONS: The non-destructive nature of this method and the ability to be applied on FFPE samples directly, allows the histopathologist to reuse of the same slide for subsequent staining and downstream analyses. Oxford University Press 2021-03-25 /pmc/articles/PMC7992223/ http://dx.doi.org/10.1093/noajnl/vdab024.084 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Supplement Abstracts Lita, Adrian Sjöberg, Joel Filipescu, Stefan Celiku, Orieta Petre, Luigia Gilbert, Mark Noushmehr, Houtan Petre, Ion Larion, Mioara TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA |
title | TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA |
title_full | TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA |
title_fullStr | TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA |
title_full_unstemmed | TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA |
title_short | TBMT-02. APOLLO: RAMAN-BASED PATHOLOGY OF MALIGNANT GLIOMA |
title_sort | tbmt-02. apollo: raman-based pathology of malignant glioma |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992223/ http://dx.doi.org/10.1093/noajnl/vdab024.084 |
work_keys_str_mv | AT litaadrian tbmt02apolloramanbasedpathologyofmalignantglioma AT sjobergjoel tbmt02apolloramanbasedpathologyofmalignantglioma AT filipescustefan tbmt02apolloramanbasedpathologyofmalignantglioma AT celikuorieta tbmt02apolloramanbasedpathologyofmalignantglioma AT petreluigia tbmt02apolloramanbasedpathologyofmalignantglioma AT gilbertmark tbmt02apolloramanbasedpathologyofmalignantglioma AT noushmehrhoutan tbmt02apolloramanbasedpathologyofmalignantglioma AT petreion tbmt02apolloramanbasedpathologyofmalignantglioma AT larionmioara tbmt02apolloramanbasedpathologyofmalignantglioma |